Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00113971
Recruitment Status : Terminated
First Posted : June 13, 2005
Last Update Posted : April 3, 2012
Information provided by (Responsible Party):
UCB Pharma

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 2007
  Actual Study Completion Date : June 2007
Kaufmann J, Wegener WA, Horak ID, et al. Pilot clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy in systemic lupus erythematosus (SLE) [abstract]. Ann Rheum Dis 2004; 63 (suppl I): Thu0443. (Published online at